Even worse, STAT3 suppresses CpG-activated immunostimulation25, suggesting the clinical demand to synergistically activate TLR9 pathway and disarm STAT3 pathway in APCs for combination cancer immunotherapy26–28. This evidence concerns the gene TLR9 and cancer.